SANN Santhera Pharmaceuticals Holding AG
Santhera Pharmaceuticals Holding AG, a specialty pharmaceutical company, together with its subsidiaries, develops and sells medicines for rare neuromuscular and pulmonary diseases with high unmet medical need in the Euro…
Industry Peers
Biotechnology| Headline | Source | Time |
|---|---|---|
Older | ||
 Santhera first-half sales double as Stifel keeps ‘buy’ rating and CHF25 target Stifel, the broker, has kept its ‘buy’ rating and CHF25 target price on Santhera Pharmaceuticals (SIX:SANN, OTC:SPHDF, FRA:S3F0), the Swiss neuromuscular drugmaker, after first-half group revenue doubled to CHF48.3 million. The company left its 2026 guidance of CHF80 million to CHF90 million... | ||
BBörse Global | ||
 Santhera nears cash break-even as AGAMREE gains traction, Edison says Santhera Pharmaceuticals (SIX:SANN, OTC:SPHDF, FRA:S3F0), the Swiss rare-disease drugmaker, is closing in on a financial turning point, according to research house Edison. In a QuickView note published on Tuesday, analysts Jyoti Prakash and Arron Aatkar said the company was on track to reach... | ||